Bruker Corporation BRKR
Composite 36/100; the shares have moved about 64% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Growth ranks 13/100 — a strong mark against it.
Momentum ranks 71/100 — a moderate point in its favour.
Growth ranks 13/100 — a strong mark against it. Quality ranks 25/100 — a moderate mark against it. Valuation ranks 25/100 — a moderate mark against it.
What the company does Bruker Corporation designs and manufactures high-performance scientific instruments and analytical solutions across life sciences, diagnostics, and industrial markets. Its segments include Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies, offering NMR/EPR systems, mass spectrometry, X-ray instruments, and automation tools.
Key financials Gross margin 47.6%, operating margin 6.2%, and net margin -0.3% reflect thin profitability despite revenue growth of 2.7%. ROE is -0.4%, ROA 2.7%, and ROCE 1.6%, with debt/equity at 0.68 and interest coverage of 1.25. Forward P/E is 15.22; EV/EBITDA stands at 35.05.
Stock health Momentum is strong with 3m, 6m, and 12m returns of 69.80%, 41.14%, and 53.03%, respectively, though down -4.62% from its 52w high. SIDERAVIA scores Quality 20.3 and Valuation 39.3, indicating poor quality and rich valuation despite positive momentum (Momentum 79.9).
Price vs fair value The stock trades at a PREMIUM of 1.40% versus our fair-value estimate of 61.38 and a PREMIUM of 4.06% versus the 12-month analyst target of 59.75. - Recent negative sentiment highlighted by “3 Reasons to Sell BRKR and 1 Stock to Buy Instead” (StockStory). - Analyst target implies limited upside versus current price. - High EV/EBITDA (35.05) and P/B (3.76) suggest valuation headwinds. - Poor quality scores (ROE -0.4%, Quality 20.3) may justify the premium discount.
Looking forward Forward P/E of 15.22 implies moderate earnings expectations. Momentum remains supportive, but thin margins and weak returns on capital warrant caution.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.